文献速递哮喘

CompEx哮喘:临床试验是否该改变终点?

CompEx Asthma: is it time for a change in clinical trials?
PubMed 文献 · Eur Respir J · 2025-09-25

本文讨论CompEx哮喘这一新型客观、以患者为中心的复合终点,它将患者报告的症状急性加重事件与重度急性发作合并,可缩短临床试验时间并减少所需患者数。文章指出哮喘控制涉及急性发作、肺功能、缓解药物使用和症状等多个维度,近期获批的重度哮喘生物制剂关键研究多依赖重度急性发作作为终点。

要点

  • CompEx哮喘复合终点结合患者报告急性加重事件与重度急性发作。
  • 该终点可缩短临床试验时间并减少所需患者数。
  • 哮喘控制涉及急性发作、肺功能、缓解药使用和症状等多维度。

核心结论

  • CompEx哮喘作为客观、以患者为中心的复合终点,有望加快临床试验进程并减少所需患者数。

主要发现

  • CompEx哮喘将患者报告定义的急性加重事件与重度急性发作合并为复合终点。
  • 哮喘控制跨越多维度,包括急性发作、肺功能、缓解药物使用和症状。
  • 近期获批的重度哮喘生物制剂关键研究多依赖重度急性发作作为终点。

临床怎么用

  • 在哮喘临床试验设计中可考虑采用CompEx哮喘复合终点以提升评估效率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CompEx Asthma is a novel objective, patient-centric composite endpoint that combines patient-reported measures to define acute worsening events with severe exacerbations, expediting timelines and reducing the number of patients needed in clinical trials https://bit.ly/4fr1grr Asthma is a heterogeneous disease. It is usually characterised by chronic airway inflammation and is defined by a history of respiratory symptoms and variable expiratory airflow limitation [1, 2]. Despite the significant advances in asthma treatment over recent years, a proportion of patients remain uncontrolled [3]. To achieve the best possible long-term outcomes for patients with asthma, new approaches are needed to improve treatment access [2]. In clinical trials, robust endpoints or outcome measures are essential to assess the efficacy and safety of the study intervention; however, asthma represents a challenge in study design because of disease control existing across multiple domains, including exacerbations, lung function as measured by spirometry (or peak flow), reliever inhaler use and symptoms. Specifically, to achieve clinical asthma remission, treatments are required that result in patients having no symptoms, no oral corticosteroid use, stable or improving lung function, and an absence of exacerbations [2]. The recent influx of approved biologics in severe asthma have mostly relied on severe exacerbations as an endpoint in pivotal studies.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Wilkinson TMA, Akuthota P. CompEx Asthma: is it time for a change in clinical trials? Eur Respir J. 2025. PMID: 40841143. doi:10.1183/13993003.00470-2025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。